Interstitial Lung Disease Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, by DelveInsight | Roche, Novartis, AdAlta, Bristol-Myers Squibb, aTyr Pharma, Avalyn Pharma

The Interstitial Lung Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

“Interstitial Lung Disease Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Interstitial Lung Disease Market.

Some of the key takeaways from the Interstitial Lung Disease Pipeline Report:

• Companies across the globe are diligently working toward developing novel Interstitial Lung Disease treatment therapies with a considerable amount of success over the years. 
• Interstitial Lung Disease companies working in the treatment market are J2H Biotech, Crystec Pharma, Apie Therapeutics, BLR Bio, AdAlta Limited, ImmunoMet Therapeutics, Genentech, Bristol-Myers Squibb, Sunshine Lake Pharma, aTyr Pharma, FibroGen, Boehringer Ingelheim, Roche, aTyr Pharma, FibroGen, LTT Bio-Pharma, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis, Horizon, MediciNova, Endeavor BioMedicines, and others, are developing therapies for the Interstitial Lung Disease treatment 

• Emerging Interstitial Lung Disease therapies in the different phases of clinical trials are- J2H P1905, CR405, APT-101, BLR-200, IM-156, AD-214, Vixarelimab, Abatacept, HEC585, Efzofitimod, Pamrevlumab, BI-1015550, RO-0220912, ATYR1923, Pamrevlumab, Zinpentraxin alfa, LT 0011, PRA023, Yifenidone, Riociguat, Treprostinil Palmitil, BMS 986278, Pirfenidone inhalation, Deupirfenidone, Ianalumab, HZN-825, Tipelukast, ENV-101, and others are expected to have a significant impact on the Interstitial Lung Disease market in the coming years.   
• In May 2023, The FDA has approved the Investigational New Drug Application (IND) for a Phase II study in patients with idiopathic pulmonary fibrosis, the most prevalent type of progressive fibrosing interstitial lung disease, according to Cumberland Pharmaceuticals Inc. (Nasdaq:CPIX). As a result, Cumberland will start its FIGHTING FIBROSIS trial, which will enrol 128 patients at more than 20 top medical institutions across the United States.
• In October 2022, Boehringer Ingelheim initiated a trial titled, “A Double Blind, Randomized, Placebo controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over at Least 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)”
• In March 2022, Cudetaxestat is an experimental non-competitive autotaxin inhibitor that is being developed for IPF and other fibrotic illnesses, according to new findings from preclinical tests released by Blade Therapeutics. A non-competitive, reversible autotaxin inhibitor known as cudetaxestat (BLD-0409) has shown direct anti-fibrotic efficacy and distinct preclinical and biochemical properties, suggesting the potential for a therapeutic profile in lung and liver fibrosis. IPF and systemic sclerosis have been given orphan drug designations for cudetaxestat
• In February 2022, Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to its novel investigational therapy, BI 1015550, for the treatment ofidiopathic pulmonary fibrosis (IPF).
• In January 2022, The first patient has joined in a Phase IIb pivotal trial, according to Horizon Therapeutics, to test the efficacy of HZN-825, a lysophosphatidic acid receptor 1 (LPAR1) antagonist being developed to treat IPF, the most common interstitial lung disease. An oral selective LPAR1 antagonist called HZN-825 has begun to have a clinical impact on systemic sclerosis. Preclinical and clinical data suggest the antifibrotic potential of LPAR1 antagonism across several organ systems, including both lung and skin. LPAR1 signalling has been linked to fibrosis and inflammation.

Interstitial Lung Disease Overview

Interstitial lung disease (ILD), also known as dispersed parenchymal illnesses, refers to a variety of diverse lung ailments that are grouped together based on common clinical, radiological, physiological, or pathologic characteristics.

Get a Free Sample PDF Report to know more about Interstitial Lung Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/interstitial-lung-disease-pipeline-insight

Emerging Interstitial Lung Disease Drugs Under Different Phases of Clinical Development Include:

• J2H P1905: J2H Biotech
• CR405: Crystec Pharma
• APT-101: Apie Therapeutics
• BLR-200: BLR Bio
• IM-156: ImmunoMet Therapeutics
• AD-214: AdAlta Limited
• Vixarelimab: Genentech
• Abatacept: Bristol-Myers Squibb
• HEC585: Sunshine Lake Pharma
• Efzofitimod: aTyr Pharma
• Pamrevlumab: FibroGen
• BI-1015550: Boehringer Ingelheim
• RO-0220912: Roche
• ATYR1923: aTyr Pharma
• Pamrevlumab: FibroGen
• Zinpentraxin alfa: Roche
• LT 0011: LTT Bio-Pharma
• PRA023: Prometheus Biosciences
• Yifenidone: HEC Pharm
• Riociguat: Bayer
• Treprostinil Palmitil: Insmed
• BMS 986278: Bristol-Myers Squibb
• DWN12088: Daewoong Pharmaceutical
• LYT-100: PureTech
• BMS-986278: Bristol-Myers Squibb
• Pirfenidone inhalation: Avalyn Pharma
• Deupirfenidone: PureTech Health
• Ianalumab: Novartis
• HZN-825: Horizon
• Tipelukast: MediciNova
• ENV-101: Endeavor BioMedicines

Route of Administration

Interstitial Lung Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types, such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Interstitial Lung Disease Pipeline Therapeutics Assessment

• Interstitial Lung Disease Assessment by Product Type
• Interstitial Lung Disease By Stage and Product Type
• Interstitial Lung Disease Assessment by Route of Administration
• Interstitial Lung Disease By Stage and Route of Administration
• Interstitial Lung Disease Assessment by Molecule Type
• Interstitial Lung Disease by Stage and Molecule Type

DelveInsight's Interstitial Lung Disease Report covers around 120+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Interstitial Lung Disease product details are provided in the report. Download the Interstitial Lung Disease pipeline report to learn more about the emerging Interstitial Lung Disease therapies

Some of the key companies in the Interstitial Lung Disease Therapeutics Market include:

Key companies developing therapies for Interstitial Lung Disease are - AdAlta, Bristol-Myers Squibb, aTyr Pharma, Avalyn Pharmaceuticals, Beijing Continent Pharmaceutical, Regend Therapeutics, Reata Pharmaceuticals, FibroGen, PureTech Health, Bellerophon Pulse Technologies, OncoArendi Therapeutics, LTT Bio-Pharma, EmphyCorp, Genentech, Cudetaxestat, Boehringer Ingelheim, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Bristol-Myers Squibb, Avalyn Pharma, Roche, Ark Biosciences, Novartis, Lung Therapeutics, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics,  Kadmon Pharmaceuticals, GenKyoTex, Taiho Pharmaceutical,Syndax Pharmaceuticals, Metagone Biotech, Galecto Biotech, CSL Behring and AstraZeneca, others.

Interstitial Lung Disease Pipeline Analysis:

The Interstitial Lung Disease pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Interstitial Lung Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Interstitial Lung Disease Treatment.
• Interstitial Lung Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Interstitial Lung Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Interstitial Lung Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Interstitial Lung Disease drugs and therapies

Interstitial Lung Disease Pipeline Market Drivers

• Increase in prevalence of Interstitial Lung Disease (ILD), increase in geriatric population are some of the important factors that are fueling the Interstitial Lung Disease Market.

Interstitial Lung Disease Pipeline Market Barriers

• However, frequent misdiagnosis of the disease, costly and invasive diagnostic procedures and other factors are creating obstacles in the Interstitial Lung Disease Market growth.

Scope of Interstitial Lung Disease Pipeline Drug Insight    

• Coverage: Global
• Key Interstitial Lung Disease Companies: J2H Biotech, Crystec Pharma, Apie Therapeutics, BLR Bio, AdAlta Limited, ImmunoMet Therapeutics, Genentech, Bristol-Myers Squibb, Sunshine Lake Pharma, aTyr Pharma, FibroGen, Boehringer Ingelheim, Roche, aTyr Pharma, FibroGen, LTT Bio-Pharma, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis, Horizon, MediciNova, Endeavor BioMedicines, and others
• Key Interstitial Lung Disease Therapies: J2H P1905, CR405, APT-101, BLR-200, IM-156, AD-214, Vixarelimab, Abatacept, HEC585, Efzofitimod, Pamrevlumab, BI-1015550, RO-0220912, ATYR1923, Pamrevlumab, Zinpentraxin alfa, LT 0011, PRA023, Yifenidone, Riociguat, Treprostinil Palmitil, BMS 986278, Pirfenidone inhalation, Deupirfenidone, Ianalumab, HZN-825, Tipelukast, ENV-101, and others
• Interstitial Lung Disease Therapeutic Assessment: Interstitial Lung Disease current marketed and Interstitial Lung Disease emerging therapies
• Interstitial Lung Disease Market Dynamics: Interstitial Lung Disease market drivers and Interstitial Lung Disease market barriers 

Request for Sample PDF Report for Interstitial Lung Disease Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services